NEW YORK/SINGAPORE (Reuters) -Asia shares rose on Thursday, tracking gains on Wall Street following a see-saw session, while ...

JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

The Dow Jones Industrial Average rose 317.24 points, or 0.71%, to 44,873.28, the S&P 500 rose 23.60 points, or 0.39%, to ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

U.S. stocks were mixed and benchmark Treasury yields slid on Wednesday as disappointing earnings and mixed economic data ...

Wall Street struggled for direction and benchmark Treasury yields slid on Wednesday as disappointing earnings and mixed economic data counterbalanced easing ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...